n.a. (ARIA)

0.00
NASDAQ
Prev Close 0.00
Day Low/High 0.00 / 0.00
52 Wk Low/High 0.00 / 0.00
Exchange NASDAQ
Div & Yield N.A. (N.A)
Jim Cramer's 'Mad Money' Recap: American Express Is Back on a Growth Track

Jim Cramer's 'Mad Money' Recap: American Express Is Back on a Growth Track

Don't ignore a big shift for American Express and don't dig in your heels, says Jim Cramer.

ARIAD Reaffirms Commitment To Discovering And Developing Treatments For Patients With Rare Cancers

ARIAD Reaffirms Commitment To Discovering And Developing Treatments For Patients With Rare Cancers

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today acknowledged the receipt of a Congressional letter and reaffirmed its commitment to discovering and developing treatments for patients with rare cancers with the...

Why Ariad Pharmaceuticals (ARIA) Stock Is Sliding Today

Why Ariad Pharmaceuticals (ARIA) Stock Is Sliding Today

Senator Bernie Sanders (I-VT) and Representative Elijah Cummings (D-MD) sent a letter to Ariad Pharmaceuticals (ARIA) today questioning the company's drug pricing.

Pardon Me, but I Have a Few Things to Say... Trump, Bernie, Radius, Ariad

Pardon Me, but I Have a Few Things to Say... Trump, Bernie, Radius, Ariad

Why Trump is killing biotech stocks, the Shire-for-Radius rumor makes no sense and Bernie Sanders gets a tweeting lesson.

Trader's Daily Notebook: You Might Consider Selling Facebook

Trader's Daily Notebook: You Might Consider Selling Facebook

Do that if you like top ticking crowd favorites, but set a protective stop.

Why Ariad (ARIA) Stock Is Plunging Today

Why Ariad (ARIA) Stock Is Plunging Today

Ariad (ARIA) stock was under pressure on Friday after Bernie Sanders rebuked the company's drug pricing practices.

'Mad Money' Lightning Round: I'm Faithful to Opko Health's CEO

'Mad Money' Lightning Round: I'm Faithful to Opko Health's CEO

Cramer is avoiding TPC Composites and is lukewarm on Kinder Morgan.

Jim Cramer's 'Mad Money' Recap: Don't Play the Short-Term Market Game

Jim Cramer's 'Mad Money' Recap: Don't Play the Short-Term Market Game

Consistency and discipline are two values this market has sorely lacked in 2016, Cramer says.

How Ariad Pharma Used a Safety Problem to Jack Up a Cancer Drug's Price

How Ariad Pharma Used a Safety Problem to Jack Up a Cancer Drug's Price

Ariad Pharmaceuticals' Iclusig now costs patients nearly $199,000 per year.

Biotech Stock Mailbag: Dynavax, Puma, Ariad

Biotech Stock Mailbag: Dynavax, Puma, Ariad

TheStreet's Adam Feuerstein answers reader questions about biotech stocks.

Ariad Pharmaceuticals (ARIA) Stock Climbs, Coverage Initiated at Leerink

Ariad Pharmaceuticals (ARIA) Stock Climbs, Coverage Initiated at Leerink

Leerink started coverage of Ariad Pharmaceuticals (ARIA) stock with an 'outperform' rating on Monday.

Ariad Pharma (ARIA) Stock Surged Today on Takeover Speculation

Ariad Pharma (ARIA) Stock Surged Today on Takeover Speculation

Ariad Pharma (ARIA) stock closed higher on Tuesday given renewed speculation that it might be a buyout target.

Ariad Pharmaceuticals (ARIA) Stock Is Monday's 'Chart of the Day'

Ariad Pharmaceuticals (ARIA) Stock Is Monday's 'Chart of the Day'

After putting in a bottom, Ariad Pharmaceuticals (ARIA) stock 'has risen like a Phoenix from the ashes,' said TheStreet's Chris Versace and Bob Lang.

Chart of the Day: Ariad

The stock price just closed above strong resistance.

ARIAD Completes Rolling Submission Of New Drug Application For Brigatinib To The U.S. Food And Drug Administration

ARIAD Completes Rolling Submission Of New Drug Application For Brigatinib To The U.S. Food And Drug Administration

ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) today announced it has completed the rolling submission of the New Drug Application (NDA) for its investigational anaplastic lymphoma kinase (ALK) inhibitor, brigatinib, to...

ARIAD To Present At The Morgan Stanley Global Healthcare Conference

ARIAD To Present At The Morgan Stanley Global Healthcare Conference

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will present at the Morgan Stanley Global Healthcare Conference being held in New York City.

Why There Is Upside for Incyte Despite Recent Selloff

Why There Is Upside for Incyte Despite Recent Selloff

The company's share price despite reporting better-than-expected earnings and revenue and

ARIAD (ARIA) Stock Pops After Q2 Beat

ARIAD (ARIA) Stock Pops After Q2 Beat

ARIAD (ARIA) stock is jumping in afternoon trading today after the company reported better-than-expected results for the second quarter before Thursday's market open.

ARIAD Reports Second Quarter And First Half 2016 Financial Results

ARIAD Reports Second Quarter And First Half 2016 Financial Results

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today reported financial results for the second quarter and first half of 2016, including revenue from sales of Iclusig ® (ponatinib).

Insider Trading Alert - SKUL, EA And ARIA Traded By Insiders

Insider Trading Alert - SKUL, EA And ARIA Traded By Insiders

Stocks with insider trader activity include SKUL, EA and ARIA

Bullish and Bearish Reversals for the Week

Bullish and Bearish Reversals for the Week

Chipotle, Wendy's on the bull side and gold stocks on the bear side.

These 5 Stocks Under $10 Are Set to Soar Higher

These 5 Stocks Under $10 Are Set to Soar Higher

Here's a technical look at how to trade five stocks trading for less than $10 a share that are headed for breakouts.

Barbarian At The Gate: ARIAD Pharmaceuticals (ARIA)

Barbarian At The Gate: ARIAD Pharmaceuticals (ARIA)

Trade-Ideas LLC identified ARIAD Pharmaceuticals (ARIA) as a "barbarian at the gate" (strong stocks crossing above resistance with today's range greater than 200%) candidate

ARIAD To Webcast Conference Call On Second Quarter 2016 Financial Results

ARIAD To Webcast Conference Call On Second Quarter 2016 Financial Results

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will report its second quarter 2016 financial results on Thursday, July 28, 2016, before the market opens.

ARIAD Announces Webcast Of Its Annual Stockholders Meeting

ARIAD Announces Webcast Of Its Annual Stockholders Meeting

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that its Annual Meeting of Stockholders will be webcast live on July 21, 2016 and can be accessed by visiting the investor relations section of the Company's...

ARIAD Pharmaceuticals (ARIA) Marked As A Dead Cat Bounce Stock

ARIAD Pharmaceuticals (ARIA) Marked As A Dead Cat Bounce Stock

Trade-Ideas LLC identified ARIAD Pharmaceuticals (ARIA) as a "dead cat bounce" (down big yesterday but up big today) candidate

ARIAD Completes Strategic Review And Announces Plans For Growth

ARIAD Completes Strategic Review And Announces Plans For Growth

ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) today announced the completion of its strategic review and its plans for future growth and vision to become a leader in the discovery, development and commercialization of...

ARIAD Announces Distribution Agreements For Iclusig® In Latin America And The Middle East/North Africa

ARIAD Announces Distribution Agreements For Iclusig® In Latin America And The Middle East/North Africa

ARIAD Pharmaceuticals, Inc. (ARIAD; NASDAQ:ARIA) today announced that it has completed two distribution agreements for Iclusig ® (ponatinib) outside of the United States.

ARIAD Initiates Submission Of New Drug Application For Brigatinib To The U.S. Food And Drug Administration Ahead Of Plan

ARIAD Initiates Submission Of New Drug Application For Brigatinib To The U.S. Food And Drug Administration Ahead Of Plan

ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) today announced the initiation of a New Drug Application (NDA) submission for its investigational anaplastic lymphoma kinase (ALK) inhibitor, brigatinib, to the U.

ARIAD Announces Long-Term Safety And Efficacy Data Of Ponatinib From Phase 2 Pace Clinical Trial

ARIAD Announces Long-Term Safety And Efficacy Data Of Ponatinib From Phase 2 Pace Clinical Trial

ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) today announced long-term follow-up data from its pivotal Phase 2 PACE clinical trial of Iclusig ® (ponatinib), its approved BCR-ABL inhibitor, in heavily pretreated...